ArticlePLoS neglected tropical diseases2025
Epidemiological situation of schistosomiasis in 16 districts of Burkina Faso after two decades of mass treatment.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Prevalence and risk factors of intestinal parasitism among schoolchildren in the municipality of Banfora, Burkina Faso.Food and waterborne parasitology · 2026Article
- Epidemiology ofParasite epidemiology and control · 2026Article
- Implications of host sex on liver metabolism duringFrontiers in cellular and infection microbiology · 2026Review
- Pathways to Diagnose Infectious Pulmonary Vascular Disease in Rural Mozambique.Infectious disease reports · 2025Article
- A model predicting the 6-year all cause mortality of patients with advanced schistosomiasis after discharge: Derived from a large population-based cohort study.PLoS neglected tropical diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundAfter two decades of mass drug administration (MDA) for schistosomiasis in Burkina Faso, an impact assessment was conducted in 16 health districts (HDs) between February 2023 to March 2024 to determine the epidemiological situation of schistosomiasis in school-aged children and facilitate the decision for sub-district level treatment decision. METHODOLOGY/PRINCIPAL
findingsA cross-sectional cluster survey was conducted with randomly selected children aged 5-14 years. Haemastix reagent strips were used to detect microhaematuria in urine, and urine filtration was used to detect and quantify Schistosoma haematobium eggs in children with microhaematuria. The Kato-Katz was used to detect and quantify S. mansoni eggs in fecal samples. The prevalence of infection and the prevalence of heavy-intensity (HI) infections were calculated. The overall prevalence of schistosomiasis was 2.4% (range: 0-11.1%) in 16 HDs, with the overall prevalence of HI infection of 0.9% (range: 0-4.2%). Four HDs (Tenkodogo, Batié, Sig-Nonghin, and Karangasso-Vigué) had a prevalence of HI infection from 1.3% to 4.2%. Forty-seven health areas still had an overall prevalence of 1.4-62.5%, with seven health areas in five HDs >10%, and 29 health areas had a prevalence of HI infection from 1.4% to 22.9%. Boys had a higher prevalence of HI infections than girls. The prevalence of microhaematuria at 5.8% was significantly higher than that of S. haematobium infection by urine filtration at 2.3%, and Haemastix results were significantly associated with the intensity of infection. CONCLUSIONS/SIGNIFICANCE: The results showed that progress has been made in eliminating schistosomiasis as a public health problem in the 16 HDs in Burkina Faso after two decades of mass treatment. However, hotspots of infections remain, with 29 health areas having a prevalence of HI infection above the 1% threshold. The results provide evidence for planning targeted sub-district-level treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.